ClinicalTrials.gg
Status unknownNCT02862483Updated Aug 12, 2016

The Efficacy and Safety of the Combination of Tamsulosin and Tadalafil in Men With Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia and Erectile Dysfunction

A Phase 3 interventional study of Tamsulosin 0.2mg and Tadalafil 5mg in Benign Prostatic Hyperplasia and Erectile Dysfunction, sponsored by IlDong Pharmaceutical Co Ltd. Status unknown at 1 site in Korea, Republic of. Open to male participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2016-08-12.

Sponsored by IlDong Pharmaceutical Co Ltd · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Aug 2016), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
330
Allocation
Randomized
Ages
45 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 48 studies testing tamsulosin in Prostatic Hyperplasia — 8 open to participants now, 8 under way, 1 of them phase 3. Tamsulosin · Prostatic Hyperplasia.

Planned enrollment
16th of 48
330 · median 118
Started
2016
with 2 others
Phase 3
11 of 48
1 open now
Registered
31st of 48
by date

Among the 48 studies testing tamsulosin in Prostatic Hyperplasia, this one is the 16th largest by planned enrollment, is one of 3 that started in 2016, is one of 11 in phase 3, and was the 31st registered.

Prostatic Hyperplasia

828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.

Browse Prostatic Hyperplasia studies →

Open to participants now

8 of the 48 studies testing tamsulosin in Prostatic Hyperplasia are open now, in 3 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About tamsulosin

Tamsulosin: first FDA approval 1997 (FLOMAX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 45 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies testing tamsulosin in Prostatic Hyperplasia, or all of them as a file.
02

Study summary

The efficacy and safety of the combination of tamsulosin and tadalafil in men with lower urinary tract symptoms due to benign prostatic hyperplasia and Erectile Dysfunction: a randomized, double blinded, parallel design, active controlled, multi-center, phase 3 clinical trial

03

Conditions studied

  • Benign Prostatic Hyperplasia
  • Erectile Dysfunction
04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Visit1

  • Male aged 45 years old or older
  • Subjects who have PSA ≤ 4.0 ng/mL Visit2
  • Subjects who have Total IPSS score ≥ 13
  • Subjects who have IIEF-EF domain ≤ 24 and each point below 3 in question 3 and 4

Exclusion criteria

Exclusion Criteria:

  • Subjects who have to product or sulfa medications
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
330 participants (estimated)

Study arms

  • Experimental
    Experimental

    Tamsulosin 0.2mg and Tadalafil 5mg

    Drug: Tamsulosin 0.2mg · Drug: Tadalafil 5mg

  • Active comparator
    Comparator

    placebo for Tamsulosin 0.2mg and Tadalafil 5mg

    Drug: Tadalafil 5mg · Drug: Placebo for Tamsulosin

Interventions

06

What researchers measure

Primary outcomes

  1. The change of total IPSS(International prostate symptom score)

    Time frame: From baseline at week 12

  2. The change of IIEF-EF(International Index of Erectile Function sum of questions-Erectile function) domain

    Time frame: From baseline at week 12

Secondary outcomes

  1. The change of total IPSS(International prostate symptom score)

    Time frame: From baseline at week 4,8

  2. The change of total IPSS(International prostate symptom score) sub score (storage, voiding)

    Time frame: From baseline at week 4,8 and 12

  3. The change of IPSS(International prostate symptom score) QoL(Quality of Life)

    Time frame: From baseline at week 4,8 and 12

  4. The change of Qmax(maximum urinary flow rate)

    Time frame: From baseline at week 4,8 and 12

  5. The change of PVR(Post Void Residual Volume)

    Time frame: From baseline at week 4,8 and 12

  6. PGIC(Patient Global Impression of change) score

    Time frame: At week 12

  7. CGIC(Clinician Global Impression of change) score

    Time frame: At week 12

  8. The change of IIEF (International Index of Erectile Function sum of questions) total score

    Time frame: From baseline at week 4,8 and 12

  9. The change of IIEF-IS(International Index of Erectile Function sum of questions-Intercourse satisfaction) domain score measured by IIEF question number 6~8

    Time frame: From baseline at week 4,8 and 12

  10. The change of OS(Overall satisfaction) domain score measured by IIEF question number13 and 14

    Time frame: From baseline at week 4,8 and 12

  11. The change of OF(Orgasmic function) domain score measured by IIEF question number 9 and 10)

    Time frame: From baseline at week 4,8 and 12

  12. The change of IIEF-EF domain(International Index of Erectile Function sum of questions-Erectile function) score measured by IIEF question number 1~5 and 15

    Time frame: From baseline at week 4,8

  13. The change of IIEF(International Index of Erectile Function) score about questions number 3 and 4

    Time frame: From baseline at week 12

  14. The percentage of patients who have more than 4 point about IIEF questions number 3 and 4

    Time frame: From baseline at week 12

  15. The percentage of patients who have increased score about IIEF questions number 3 and 4(at least 1 point) compared to the baseline

    Time frame: From baseline at week 12

07

Study locations

1 of 1 sites recruiting
  • Catholic university of korea, Seoul ST. Mary's Hospital.
    Seoul, Korea, Republic of
    Recruiting
    • Sae Woong Kim · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2016, a primary completion of Mar 2017 and a completion of Mar 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2016
First posted
Aug 11, 2016
Start
Mar 2016
Primary completionEst.
Mar 2017
CompletionEst.
Mar 2017
Last update
Aug 12, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02862483
Responsible party
Sponsor
First posted
Aug 11, 2016
Start date
Mar 2016
Primary completion
Mar 2017 (estimated)
Completion
Mar 2017 (estimated)
Last update
Aug 12, 2016

Study contacts

Ji-yoon Choi
Contact
jychoi@ildong.com

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tamsulosin

Start the discussion